BRAF<sup>V600E</sup> mutation: A promising target in colorectal neuroendocrine carcinoma
Levent Dizdar(Düsseldorf University Hospital), Andreas Krieg(Düsseldorf University Hospital)
Cited by 43
Related Papers
Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment
|Journal of Cancer Research and Clinical Oncology|2021|4